Natural product drug discovery from microalgae

Microalgal Biotechnology: Integration and Economy

Volumn , Issue , 2012, Pages 169-200

  Niedermeyer, Timo ^a   Brönstrup, Mark ^b  

^a CYANO BIOTECH GMBH   (Germany)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85119875371     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (218)

1. Al-Awar, R. S. and Chuan Shih. 2005. The Isolation, Characterization, and Development of a Novel Class of Potent Antimitotic Macrocyclic Depsipeptides: The Cryptophycins. In: Anticancer agents from natural products, ed. David Kingston, Gordon Cragg and David Newman. CRC Press. pp. 151-170.
2. van Apeldoorn, M. E., H. P. van Egmond, G. J. A. Speijers and G. J. I. Bakker. 2007. Toxins of cyanobacteria. Molecular Nutrition & Food Research 51: 7-60.
3. Barbaras, D., M. Kaiser, R. Brun and K. Gademann. 2008. Potent and selective antiplasmodial activity of the cyanobacterial alkaloid nostocarboline and its dimers. Bioorganic & Medicinal Chemistry Letters 18: 4413-4415.
4. Barrios-llerena, M. E., A. M. Burja and P. C. Wright. 2007. Genetic analysis of polyketide synthase and peptide synthetase genes in cyanobacteria as a mining tool for secondary metabolites. Journal Of Industrial Microbiology and Biotechnology 34: 443-456.
5. Bauer, I., L. Maranda, K. A. Young, Y. Shimizu, C. Fairchild, L. Cornell, J. MacBeth and S. Huang. 1995. Isolation and Structure of Caribenolide I, a Highly Potent Antitumor Macrolide from a Cultured Free-swimming Caribbean Dinoflagellate, Amphidinium sp. S1-36-5. Journal of Organic Chemistry 60: 1084-1086.
6. Becher, P. G., J. Beuchat, K. Gademann and Friedrich Jüttner. 2005. Nostocarboline: Isolation and Synthesis of a New Cholinesterase Inhibitor from Nostoc 78-12A. Journal of Natural Products 68: 1793-1795.
7. Berry, J. P., M. Gantar, M. H. Perez, G. Berry and Fernando G. Noriega. 2008. Cyanobacterial Toxins as Allelochemicals with Potential Applications as Algaecides, Herbicides and Insecticides. Marine Drugs 6: 117-146.
8. Bhansali, P., C. L. Hanigan, R. A. Casero Jr. and L. M. V. Tillekeratne. 2011. Largazole and Analogues with Modified Metal-Binding Motifs Targeting Histone Deacetylases: Synthesis and Biological Evaluation. Journal of Medicinal Chemistry 54: 7453-7463.
9. Bjorquist, P., M. Buchanan, M. Campitelli, A. Carroll, E. Hyde, J. Neve, R. Quinn and M. Polla. 2008. Use of Cyclic Anabaenopeptin-Type Peptides for the Treatment of a Condition Wherein Inhibition of Carboxypeptidase U in Beneficial, Novel Anabaenopeptin Derivatives and Intermediates Thereof. US Patent 2008/0039376 A1
10. Blom, J. F., T. Brütsch, D. Barbaras, Y. Bethuel, H. H. Locher, C. Hubschwerlen and K. Gademann. 2006. Potent Algicides Based on the Cyanobacterial Alkaloid Nostocarboline. Organic Letters 8: 737-740.
11. Bonazzi, S., D. Barbaras, L. Patiny, R. Scopelliti, P. Schneider, S. T. Cole, M. Kaiser, R. Brun and K. Gademann. 2010. Antimalarial and antitubercular nostocarboline and eudistomin derivatives: Synthesis, in vitro and in vivo biological evaluation. Bioorganic & Medicinal Chemistry 18: 1464-1476.
12. Bonjouklian, R., R. E. Moore, J. S. Mynderse, G. M. L. Patterson and T. A. Smitka. 1989. Hapalindoles. US Patent 4, 870, 185.
13. Bonjouklian, R., T. A. Smitka, A. H. Hunt, J. L. Occolowitz, T. J. Perun Jr., L. Doolin, S. Stevenson, L. Knauss, R. Wijayaratne, S. Szewczyk and G. M. L. Patterson. 1996. A90720A, A Serine Protease Inhibitor Isolated From A Terrestrial Blue-Green Alga Microchaete loktakensis. Tetrahedron 52: 395-404.
14. Borowitzka, M. A. 1995. Microalgae as sources of pharmaceuticals and other biologically active compounds. Journal of Applied Phycology 7: 3-15.
15. Botes, D. P., P. L. Wessels, H. Kruger, M. T. C. Runnegar, S. Santikarn, R. J. Smith, J. C. J. Barna and D. H. Williams. 1985. Structural Studies on Cyanoginosins-LR, -YR, -YA, and -YM, Peptide Toxins from Microcystis aeruginosa. Journal of the Chemical Society, Perkin Transactions I 1: 2747-2748.
16. Bouchard, H., M.-P. Brun, A. Commerçon and J. Zhang. 2010. Novel Conjugates, Preparations Thereof, and Therapeutic Use Thereof. Patent WO/2011/001052
17. Bowers, A. A., N. West, T. L. Newkirk, A. E. Troutman-Youngman, S. L. Schreiber, O. Wiest, J. E. Bradner and R. M. Williams. 2009a. Synthesis and Histone Deacetylase Inhibitory Activity of Largazole Analogs: Alteration of the Zinc-Binding Domain and Macrocyclic Scaffold. Organic Letters 11: 1301-1304.
18. Bowers, A. A., T. J. Greshock, N. West, G. Estiu, S. L. Schreiber, O. Wiest, R. M. Williams and J. E. Bradner. 2009b. Synthesis and Conformation-Activity Relationships of the Peptide Isosteres of FK228 and Largazole. Journal of the American Chemical Society 131: 2900-2905.
19. Bowers, A., N. West, J. Taunton, S. L. Schreiber, J. E. Bradner and R. M. Williams. 2008. Total synthesis and biological mode of action of largazole: a potent class I histone deacetylase inhibitor. Journal of the American Chemical Society 130: 11219-22.
20. Boyd, M. R., K. R. Gustafson, J. B. McMahon, R. H. Shoemaker, B. R. O'Keefe, T. Mori, R. J. Gulakowski, L. Wu, M. I. Rivera, C. M. Laurencot, M. J. Currens, J. H. Cardellina 2nd, R. Buckheit Jr., P. L. Nara, L. K. Pannell, R. C. Sowder 2nd and L. E. Henderson. 1997. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrobial Agents and Chemotherapy 41: 1521-1530.
21. Burja, A. M., B. Banaigs, E. Abou-Mansour, J. G. Burgess and P. C. Wright. 2001. Marine cyanobacteria-aprolific source of natural products. Tetrahedron 57: 9347-9377.
22. Butler, M. S. 2004. The role of natural product chemistry in drug discovery. Journal of Natural Products 67: 2141-53.
23. Butler, M. S. 2008. Natural products to drugs: natural product-derived compounds in clinical trials. Natural Product Reports 25: 475-516.
24. Campos, A. and V. Vasconcelos. 2010. Molecular Mechanisms of Microcystin Toxicity in Animal Cells. International Journal of Molecular Sciences 11: 268-287.
25. Cannell, R. J. P. 1993. Algae as a Source of Biologically Active Products. Pesticide Science 39: 147-153.
26. Cao, Z., W. H. Gerwick and T. F. Murray. 2010. Antillatoxin is a sodium channel activator that displays unique efficacy in heterologously expressed rNav1.2, rNav1.4 and rNav1.5 alpha subunits. BMC Neuroscience 11: 154-166.
27. Carmichael, W. W., V. Beasley, D. L. Bunner, J. N. Eloff, I. Falconer, P. Gorham, K.-I. Harada, T. Krishnamurty, Y. Min-Juan, R. E. Moore, K. Rinehart, M. Runnegar, O. M. Skulberg and M. Watanabe. 1988. Naming of Cyclic Heptapeptide Toxins of Cyanobacteria (Blue-Green Algae). Toxicon 26: 971-973.
28. Cetusic, J. R. P., F. R. Green III, P. R. Graupner and M. P. Oliver. 2002. Total Synthesis of Hectochlorin. Organic Letters 4: 1307-1310.
29. Challis, G. L. and J. H. Naismith. 2004. Structural aspects of non-ribosomal peptide biosynthesis. Current Opinion in Structural Biology 14: 748-756.
30. Chang, Z., P. Flatt, W. H. Gerwick, V.-A. Nguyen, C. L. Willis and D. H. Sherman. 2002. The barbamide biosynthetic gene cluster: a novel marine cyanobacterial system of mixed polyketide synthase (PKS)-non-ribosomal peptide synthetase (NRPS) origin involving an unusual trichloroleucyl starter unit. Gene 296: 235-247.
31. Chen, J. L., R. E. Moore and G. M. L. Patterson. 1991. Structures of Nostocyclophanes A-D. Journal of Organic Chemistry 56: 4360-4364.
32. Chen, J. and C. J. Forsyth. 2003. Total Synthesis of Apratoxin A. Journal of the American Chemical Society 125: 8734-8735.
33. Cohen, P. T. W. 2010. Sorting the protein phosphatases: okadaic acid led the way. Biochemistry Journal: 256: 1-5.
34. Colombo, D., A. Scala, I. M. Taino, L. Toma, F. Ronchetti, H. Tokuda, H. Nishino, A. Nagatsu and J. Sakakibara. 1998. Inhibitory effects of fatty acid monoesters of 2-O-b-d-glucosylglycerol on Epstein-Barr virus activation. Cancer Letters 123: 83-86.
35. Costa, L. G., G. Giordano and E. M. Faustman. 2010. Domoic acid as a developmental neurotoxin. NeuroToxicology 31: 409-423.
36. Cragg, G. M., P. G. Grothaus and D. J. Newman. 2009. Impact of natural products on developing new anti-cancer agents. Chemical Reviews 109: 3012-43.
37. Daily, A., N. R. Monks, M. Leggas and J. A. Moscow. 2010. Abrogation of microcystin cytotoxicity by MAP kinase inhibitors and N-acetyl cysteine is confounded by OATP1B1 uptake activity inhibition. Toxicon 55: 827-837.
38. Daranas, A. H., M. Norte and J. J. Fernández. 2001. Toxic marine microalgae. Toxicon 39: 1101-1132.
39. Dawson, R. M. 1998. The Toxicology of Microcystins. Toxicon 36: 953-962.
40. Dinh, T. Q. and R. W. Armstrong. 1995. A Convergent Total Synthesis of the Multidrug Resistance-Reversing Agent Hapalosin. Journal of Organic Chemistry 60: 8118-8119.
41. Dittmann, E., B. A. Neilan and T. Börner. 2001. Molecular biology of peptide and polyketide biosynthesis in cyanobacteria. Applied Microbiology and Biotechnology 57: 467-473.
42. DNP (Dictionary of Natural Products on DVD). Taylor & Francis Group. 2011.
43. Donia, M. S., J. Ravel and E. W. Schmidt. 2008. A global assembly line for cyanobactins. Nature Chemical Biology 4: 341-343.
44. Donia, M. S. and E. W. Schmidt. 2010. Cyanobactins - Ubiquitous Cyanobacterial Ribosomal Peptide Metabolites. In: Comprehensive Natural Products II: Chemistry and Biology,ed. Lewis Mander and Hung-Wen Liu. Elsevier. pp. 14-17.
45. Doronina, S. O., B. E. Toki, M. Y. Torgov, B. A. Mendelsohn, C. G. Cerveny, D. F. Chace, R. L. Deblanc, R. P. Gearing, T. D. Bovee, C. B. Siegall, J. A. Francisco, A. F. Wahl, D. L. Meyer and P. D. Senter. 2003. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nature Biotechnology 21: 778-785.
46. Driggers, E. M., S. P. Hale, J. Lee and N. K. Terrett. 2008. The exploration of macrocycles for drug discovery - an underexploited structural class. Nature Reviews Drug Discovery 7: 608-624.
47. D'Agostino, G., J. del Campo, B. Mellado, MA. Izquierdo, T. Minarik, L. Cirri, L. Marini, J. L. Perez-Gracia and G. Scambia. 2006. A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer. International Journal of Gynecological Cancer 16: 71-76.
48. Edelman, M. J., D. R. Gandara, P. Hausner, V. Israel, D. Thornton, J. Desanto and L. A. Doyle. 2003. Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. Lung Cancer 39: 197-199.
49. Eggen, M. and G. I. Georg. 2002. The Cryptophycins: Their Synthesis and Anticancer Activity. Medicinal Research Reviews 22: 85-101.
50. Eißler, S., A. Stoncius, M. Nahrwold and N. Sewald. 2006. The Synthesis of Cryptophycins. Synthesis 22: 3747-3789.
51. Finking, R. and M. Marahiel. 2004. Biosynthesis of nonribosomal peptides. Annual Review of Microbiology 58: 453-88.
52. Flahive, E. and J. Srirangam. 2005. The Dolastatins: Novel Antitumor Agents from Dolabella auricularia. In: Anticancer agents from natural products, ed. David Kingston, Gordon Cragg, and David Newman. CRC Press. pp. 191-214.
53. Furey, A., J. García, K. O'Callaghan, M. Lehane, M. F. Amandi and K. J. James. 2007. Brevetoxins: Structure, Toxicology, and Origin. In: Phycotoxins: Chemistry and Biochemistry, ed. Luis M Botana. Blackwell Publishing. pp. 19-46.
54. Gademann, K. 2011. Out in the Green: Biologically Active Metabolites Produced by Cyanobacteria. Chimia 65: 416-419.
55. Gademann, K., C. Portmann, J. F. Blom, M. Zeder and F. Jüttner. 2010. Multiple Toxin Production in the Cyanobacterium Microcystis: Isolation of the Toxic Protease Inhibitor Cyanopeptolin 1020. Journal of Natural Products 73: 980-984.
56. Gademann, K. and J. Kobylinska. 2009. Antimalarial Natural Products of Marine and Freshwater Origin. The Chemical Record 9: 187-198.
57. Gademann, K. and C. Portmann. 2008. Secondary Metabolites from Cyanobacteria: Complex Structures and Powerful Bioactivities. Current Organic Chemistry 12: 326-341.
58. Genzyme Corporation. Website on Tasidotin Hydrochloride, http://www.genzymeoncology.com/ onc/research/onc_p_tasidotinHydrochloride.asp, accessed on 25. 03. 2012.
59. Gerwick, W. H., R. C. Coates, N. Engene, L. Gerwick, R. V. Grindberg, A. C. Jones and C. M. Sorrels. 2008. Giant Marine Cyanobacteria Produce Exciting Potential Pharmaceuticals. Microbe 3: 277-284.
60. Gerwick, W. H., P. J. Proteau, D. G. Nagle, E. Hamel, A. Blokhin and D. L. Slates. 1994. Structure of Curacin A, a Novel Antimitotic, Antiproliferative, and Brine Shrimp Toxic Natural Product from the Marine Cyanobacterium Lyngbya majuscula. Journal of Organic Chemistry 59: 1243-1245.
61. Gustafson, K. R., J. H. Cardellina I. I., R. W. Fuller, O. S. Weislow, R. F. Kiser, K. M. Snader, G. M. L. Patterson and M. R. Boyd. 1989. AIDS-Antiviral Sulfolipids From Cyanobacteria (Blue-Green Algae). Journal of the National Cancer Institute 81: 1254-1258.
62. Guyot, M., J. C. Doré and J. Devillers. 2004. Typology of Secondary Cyanobacterial Metabolites from Minimum Spanning Tree Analysis. SAR and QSAR in Environmental Research 15: 101-114.
63. Hagenbuch, B. and C. Gui. 2008. Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 38: 778-801.
64. Han, B., H. Gross, D. E. Goeger, S. L. Mooberry and W. H. Gerwick. 2006. Aurilides B. and C., Cancer Cell Toxins from a Papua New Guinea Collection of the Marine Cyanobacterium Lyngbya majuscula. Journal of Natural Products 69: 572-575.
65. Harada, K.-i. 2004. Production of Secondary Metabolites by Freshwater Cyanobacteria. Chemical & Pharmaceutical Bulletin 52: 889-899.
66. Harrigan, G. G. and G. Goetz. 2002. Symbiotic and dietary marine microalgae as a source of bioactive molecules - experience from natural products research. Journal of Applied Phycology 14: 103-108.
67. Harvey, A. L. 2008. Natural products in drug discovery. Drug Discovery Today 13: 894-901.
68. Hershberger, S. J., S.-G. Lee and J. Chmielewski. 2007. Scaffolds for Blocking Protein-Protein Interactions. Current Topics in Medicinal Chemistry 7: 928-942.
69. Hirsch, C. F., J. M. Liesch, M. J. Salvatore, R. E. Schwartz and D. F. Sesin. 1990. Antifungal Fermentation Product and Method. US Patent 4,946,835
70. Hoppe, H. A. 1979. Marine algae and their products and constituents in pharmacy. In: Marine Algae in Pharmaceutical Science. Ed. H. A. Hoppe, T. Levring and Y. Tanaka. de Gruyter. pp. 25-119.
71. Huskens, D., G. Férir, K. Vermeire, J.-C. Kehr, J. Balzarini, E. Dittmann and D. Schols. 2010. Microvirin, a Novel alpha(1,2)-Mannose-specific Lectin Isolated from Microcystis aeruginosa, Has Anti-HIV-1 Activity Comparable with That of Cyanovirin-N but a Much Higher Safety Profile. Journal of Biological Chemistry 285: 24845-24854.
72. Huskens, D., K. Vermeire, E. Vandemeulebroucke, J. Balzarini and D. Schols. 2008. Safety concerns for the potential use of cyanovirin-N as a microbicidal anti-HIV agent. International Journal of Biochemistry and Cell Biology 40: 2802-2814.
73. Ishida, K., T. Kato, M. Murakami, M. Watanabe and M. F. Watanabe. 2000. Microginins, Zinc Metalloproteases Inhibitors from the Cyanobacterium Microcystis aeruginosa. Tetrahedron 56: 8643-8656.
74. Ishida, K., H. Matsuda, M. Murakami and K. Yamaguchi. 1997. Kawaguchipeptin B, an Antibacterial Cyclic Undecapeptide from the Cyanobacterium Microcystis aeruginosa. Journal of Natural Products 60: 724-726.
75. Jaki, B., O. Zerbe, J. Heilmann and O. Sticher. 2001. Two Novel Cyclic Peptides with Antifungal Activity from the Cyanobacterium Tolypothrix byssoidea (EAWAG 195). Journal of Natural Products 64: 154-158.
76. Jaki, B., J. Orjala and O. Sticher. 1999. A Novel Extracellular Diterpenoid with Antibacterial Activity from the Cyanobacterium Nostoc commune. Journal of Natural Products 62: 502-503.
77. Jaspars, M. and L. A. Lawton. 1998. Cyanobacteria-anovelsource of pharmaceuticals. Current Opinion in Drug Discovery & Development 1: 77-84.
78. Jones, A. C., L. Gu, C. M. Sorrels, D. H. Sherman and W. H. Gerwick. 2009. New tricks from ancient algae: natural products biosynthesis in marine cyanobacteria. Current Opinion in Chemical Biology 13: 216-223.
79. Jones, A. C., E. A. Monroe, E. B. Eisman, L. Gerwick, H. Sherman and W. H. Gerwick. 2010. The unique mechanistic transformations involved in the biosynthesis of modular natural products from marine cyanobacteria. Natural Product Reports 27: 1048-1065.
80. Kalaitzis, J. A., F. M. Lauro and B. A. Neilan. 2009. Mining cyanobacterial genomes for genes encoding complex biosynthetic pathways. Natural Product Reports 26: 1447-1465.
81. Kalliokoski, A. and M. Niemi. 2009. Impact of OATP transporters on pharmacokinetics. British Journal of Pharmacology 158: 693-705.
82. Kang, H.-S., A. Krunic, Q. Shen, S. M. Swanson and J. Orjala. 2011. Minutissamides A-D, Antiproliferative Cyclic Decapeptides from the Cultured Cyanobacterium Anabaena minutissima. Journal of Natural Products 74: 1597-1605.
83. Katz, J., J. E. Janik and A. Younes. 2011. Brentuximab Vedotin (SGN-35). Clinical Cancer Research 17: 6428-6436.
84. Kehr, J.-C., D. G. Picchi and E. Dittmann. 2011. Natural product biosyntheses in cyanobacteria: A treasure trove of unique enzymes. Beilstein Journal of Organic Chemistry 7: 1622-1635.
85. Kindler, H. L., P. K. Tothy, R. Wolff, R. A. McCormack, J. L. Abbruzzese, S. Mani, K. T. Wade-Oliver and E. E. Vokes. 2005. Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers. Investigational New Drugs 23: 489-493.
86. Kobayashi, J. 2008. Amphidinolides and its related macrolides from marine dinoflagellates. Journal of Antibiotics 61: 271-284.
87. Kobayashi, J. and Takaaki Kubota. 2010. Bioactive Metabolites from Marine Dinoflaggelates. In: Comprehensive Natural Products II: Chemistry and Biology, ed. Lewis Mander and Hung-Wen Liu. Elsevier. pp. 263-325.
88. Krishnamurthy, T., W. W. Carmichael and E. W. Sarver. 1986. Toxic peptides from freshwater cyanobacteria (blue-green algae). I. Isolation, purification and characterization of peptides from Microcystis aeruginosa and Anabaena flos-aquae. Toxicon 24: 865-873.
89. Kungsuwan, A., T. Noguchi, S. Matsunaga, M. F. Watanabe, S. Watabe and K. Hashimoto. 1988. Properties of two toxins isolated from the blue-green alga Microcystis aeruginosa. Toxicon 26: 119-125.
90. Kwan, J. C., R. Ratnayake, K. A. Abboud, V. J. Paul and H. Luesch. 2010. Grassypeptolides A-C, cytotoxic bis-thiazoline containing marine cyclodepsipeptides. Journal of Organic Chemistry 75: 8012-8023.
91. König, J., A. Seithel, U. Gradhand and M. F. Fromm. 2006. Pharmacogenomics of human OATP transporters. Naunyn-Schmiedeberg's Archives of Pharmacology 372: 432-443.
92. Lambert, J. M. 2005. Drug-conjugated monoclonal antibodies for the treatment of cancer. Current Opinion in Pharmacology 5: 543-549.
93. LePage, K. T., D. Goeger, F. Yokokawa, T. Asano, T. Shioiri, W. H. Gerwick and T. F. Murray. 2005. The neurotoxic lipopeptide kalkitoxin interacts with voltage-sensitive sodium channels in cerebellar granule neurons. Toxicology Letters 158: 133-139.
94. Lee, W., A. Belkhiri, A. C. Lockhart, N. Merchant, H. Glaeser, E. I. Harris, M. K. Washington, E. M. Brunt, A. Zaika, R. B. Kim and W. El-Rifai. 2008. Overexpression of OATP1B3 Confers Apoptotic Resistance in Colon Cancer. Cancer Research 68: 10315-10323.
95. Lin, Y.-Y., M. Risk, S. M. Ray, D. van Engen, J. Clardy, J. Golik, J. C. James and K. Nakanishi. 1981. Isolation and Structure of Brevetoxin B from the "Red Tide" Dinoflaggelate Ptychodiscus brevis (Gymnodinium breve). Journal of the American Chemical Society 103: 6773-6775.
96. Linington, R. G., D. J. Edwards, C. F. Shuman, K. L. McPhail, T. Matainaho and W. H. Gerwick. 2008. Symplocamide A, a Potent Cytotoxin and Chymotrypsin Inhibitor from the Marine Cyanobacterium Symploca sp. Journal of Natural Products 71: 22-27.
97. Linington, R. G. and L. M. Sanchez. 2010. Novel Anti-Parasitic Compounds. United States. Patent WO 2010/108164
98. Liu, L. and K. S. Rein. 2010. New Peptides Isolated from Lyngbya Species: A Review. Marine Drugs 8: 1817-1837.
99. Liu, Y., B. K. Law and H. Luesch. 2009. Apratoxin A Reversibly Inhibits the Secretory Pathway by Preventing Cotranslational Translocation. Molecular Pharmacology 76: 91-104.
100. Llewellyn, L. E. 2006. Saxitoxin, a toxic marine natural product that targets a multitude of receptors. Natural Product Reports 23: 200-22.
101. Locher, H. H., D. Ritz, P. Pfaff, M. Gaertner, A. Knezevic, D. Sabato, S. Schroeder, D. Barbaras and K. Gademann. 2010. Dimers of Nostocarboline with Potent Antibacterial Activity. Chemotherapy 56: 318-324.
102. Luesch, H., G. G. Harrigan, G. Goetz and F. D. Horgen. 2002. The Cyanobacterial Origin of Potent Anticancer Agents Originally Isolated from Sea Hares. Current Medicinal Chemistry 9: 1791-1806.
103. Luesch, H., S. K. Chanda, R. M. Raya, P. D. DeJesus, A. P. Orth, J. R. Walker, J. C. I. Belmonte and P. G. Schultz. 2006. A functional genomics approach to the mode of action of apratoxin A. Nature Chemical Biology 2: 158-167.
104. Luesch, H., W. Y. Yoshida, R. E. Moore, V. J. Paul and T. H. Corbett. 2001. Total Structure Determination of Apratoxin A, a Potent Novel Cytotoxin from the Marine Cyanobacterium Lyngbya majuscula. Journal of the American Chemical Society 123: 5418-5423.
105. MacMillan, J. B. and T. F. Molinski. 2002. Caylobolide A., a Unique 36-Membered Macrolactone from a Bahamian Lyngbya majuscula. Organic Letters 4: 1535-1538.
106. MacMillan, J. B. and T. F. Molinski. 2005. Majusculoic Acid, a Brominated Cyclopropyl Fatty Acid from a Marine Cyanobacterial Mat Assemblage. Journal of Natural Products 68: 604-606.
107. Malloy, K. L., F. A. Villa, N. Engene, T. Matainaho, L. Gerwick and W. H. Gerwick. 2011. Malyngamide 2, an Oxidized Lipopeptide with Nitric Oxide Inhibiting Activity from a Papua New Guinea Marine Cyanobacterium. Journal of Natural Products 74: 95-98.
108. Marahiel, M. 2009. Working outside the protein-synthesis rules: insights into non-ribosomal peptide synthesis. Journal of Peptide Science 15: 799-807.
109. Marquez, B. L., K. S. Watts, A. Yokochi, M. A. Roberts, P. Verdier-Pinard, J. I. Jimenez, E. Hamel, P. J. Scheuer and W. H. Gerwick. 2002. Structure and Absolute Stereochemistry of Hectochlorin, a Potent Stimulator of Actin Assembly. Journal of Natural Products 65: 866-871.
110. Matsuda, H., T. Okino, M. Murakami and K. Yamaguchi. 1996. Aeruginosins 102-A and B, New Thrombin Inhibitors from the Cyanobacterium Microcystis viridis (NIES-102). Tetrahedron 52: 14501-14506.
111. Medina, R. A., D. E. Goeger, P. Hills, S. L. Mooberry, N. Huang, L. I. Romero, E. Ortega-Barría, W. H. Gerwick and K. L. McPhail. 2008. Coibamide A, a Potent Antiproliferative Cyclic Depsipeptide from the Panamanian Marine Cyanobacterium Leptolyngbya sp. Journal of the American Chemical Society 130: 6324-6325.
112. Meeks, J. C., J. Elhai, T. Thiel, M. Potts, F. Larimer, J. Lamerdin, P. Predki and R. Atlas. 2001. An overview of the genome of Nostoc punctiforme, a multicellular, symbiotic cyanobacterium. Photosynthesis Research 70: 85-106.
113. von Mehren, M., S. P. Balcerzak, A. S. Kraft, J. H. Edmonson, S. H. Okuno, M. Davey, S. McLaughlin, M. T. Beard and A. Rogatko. 2004. Phase II trial of dolastatin-10, a novel anti-tubulin agent, in metastatic soft tissue sarcomas. Sarcoma 8: 107-111.
114. Meriluoto, J. and G. A. Codd, eds. 2005. Toxic: Cyanobacterial Monitoring and Cyanotoxin Analysis. Mathematica. Abo Akademi University Press.
115. Metting, B. and J. W. Pyne. 1986. Biologically active compounds from microalgae. Enzyme and Microbial Technology 8: 386-394.
116. Metting, F. B. 1996. Biodiversity and application of microalgae. Journal of Industrial Microbiology 17: 477-489.
117. Mo, S., A. Krunic, S. D. Pegan, S. G. Franzblau and J. Orjala. 2009. An Antimicrobial Guanidine-Bearing Sesterterpene from the Cultured Cyanobacterium Scytonema sp. Journal of Natural Products 72: 2043-2045.
118. Monks, N. R., S. Liu and J. A. Moscow. 2007a. Microcystins as Agents for Treatment of Cancer. United States. US Patent 2007/0275885
119. Monks, N. R., S. Liu, Y. Xu, H. Yu, A. S. Bendelow and J. A. Moscow. 2007b. Potent cytotoxicity of the phosphatase inhibitor microcystin LR and microcystin analogues in OATP1B1- and OATP1B3-expressing HeLa cells. Molecular cancer therapeutics 6: 587-598.
120. Moore, R. E. 1996. Cyclic peptides and depsipeptides from cyanobacteria: a review. Journal Of Industrial Microbiology 16: 134-143.
121. Moore, R. E., C. Cheuk, X.-Q. G. Yang, G. M. L. Patterson, R. Bonjouklian, T. A Smitka, J. S Mynderse, R. S. Foster, N. D. Jones, J. K. Swartzendruber and J. B. Deeter. 1987. Hapalindoles, Antibacterial and Antimycotic Alkaloids from the Cyanophyte Hapalosiphon fontinalis. Journal of Organic Chemistry 52: 1036-1043.
122. Mos, L. 2001. Domoic acid: a fascinating marine toxin. Environmental Toxicology and Pharmacology 9: 79-85.
123. Murakami, M., K. Makabe, K. Yamaguchi, S. Konosu and M. R. Walchli. 1988. Goniodomin A, a novel polyether macrolide from the dinoflagellate Goniodoma pseudogoniaulax. Tetrahedron Letters 29: 1149-1152.
124. Murata, M., M. Shimatani, H. Sugitani, Y. Oshima and T. Yasumoto. 1982. Isolation and Structural Elucidation of the Causative Toxin of the Diarrhetic Shellfish Poisoning. Bulletin of the Japanese Society of Scientific Fisheries 48: 549-552.
125. Muto, M., T. Onogawa, T. Suzuki, T. Ishida, T. Rikiyama, Y. Katayose, N. Ohuchi, H. Sasano, T. Abe and M. Unno. 2007. Human liver-specific organic anion transporter-2 is a potent prognostic factor for human breast carcinoma. Cancer Science 98: 1570-1576.
126. Nagai, H., M. Murata, K. Torigoe, M. Satake and T. Yasumoto. 1992. Gambieric Acids, New Potent Antifungal Substances with Unprecedented Polyether Structures from a Marine Dinoflagellate Gambierdiscus toxicus. Journal of Organic Chemistry 57: 5448-5453.
127. Nagle, D. G. and V. J. Paul. 1999. Production of secondary metabolites by filamentous tropical marine cyanobacteria: ecological functions of the compounds. Journal of Phycology 35: 1412-1421.
128. Namikoshi, M. and K. L. Rinehart. 1996. Bioactive compounds produced by cyanobacteria. Journal of Industrial Microbiology & Biotechnology 17: 373-384.
129. Neuhof, T., P. Schmieder, K. Preussel, R. Dieckmann, H. Pham, F. Bartl and H. von Döhren. 2005. Hassallidin A, a Glycosylated Lipopeptide with Antifungal Activity from the Cyanobacterium Hassallia sp. Journal of Natural Products 68: 695-700.
130. Newman, D. J. 2008. Natural products as leads to potential drugs: an old process or the new hope for drug discovery? Journal of Medicinal Chemistry 51: 2589-99.
131. Newman, D. J. and G. M. Cragg. 2012. Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010. Journal of Natural Products 75: 311-335.
132. Nicolaou, K. C., M. O. Frederick and R. J. Aversa. 2008. The continuing saga of the marine polyether biotoxins. Angewandte Chemie (International ed. in English) 47: 7182-7225.
133. Nogle, L. M., T. Okino and W. H. Gerwick. 2001. Antillatoxin B, a Neurotoxic Lipopeptide from the Marine Cyanobacterium Lyngbya majuscula. Journal of Natural Products 64: 983-985.
134. Nogle, L. M. and W. H. Gerwick. 2002. Somocystinamide A, a Novel Cytotoxic Disulfide Dimer from a Fijian Marine Cyanobacterial Mixed Assemblage. Organic Letters 4: 1095-1098.
135. Okano, T., T. Sano and K. Kaya. 1999. Micropeptin T-20, A Novel Phosphate-containing Cyclic Depsipeptide from the Cyanobacterium Microcystis aeruginosa. Tetrahedron Letters 40: 2379-2382.
136. Okino, T., M. Murakami, R. Haraguchi, H. Munekata, H. Matsuda and K. Yamaguchi. 1993. Micropeptins A and B, Plasmin and Trypsin Inhibitors from the Blue-Green Alga Microcystis aeruginosa. Tetrahedron Letters 34: 8131-8134.
137. Olaizola, M. 2003. Commercial development of microalgal biotechnology: from the test tube to the marketplace. Biomolecular Engineering 20: 459-466.
138. Orjala, J. and W. H. Gerwick. 1996. Barbamide, a chlorinated metabolite with molluscicidal activity from the Caribbean cyanobacterium Lyngbya majuscula. Journal of Natural Products 59: 427-30.
139. Orjala, J., D. G. Nagle, V. L. Hsu and W. H. Gerwick. 1995. Antillatoxin: An Exceptionally Ichthyotoxic Cyclic Lipopeptide from the Tropical Cyanobacterium Lyngbya majuscula. Journal of the American Chemical Society 117: 8281-8282.
140. O'Keefe, B. R., D. F. Smee, J. A. Turpin, C. J. Saucedo, K. R. Gustafson, T. Mori, D. Blakeslee, R. Buckheit and M. R. Boyd. 2003. Potent Anti-Influenza Activity of Cyanovirin-N and Interactions with Viral Hemagglutinin. Antimicrobial Agents and Chemotherapy 47: 2518-2525.
141. Paik, S., S. Carmeli, J. Cullingham, R. E. Moore, G. M. L. Patterson and M. A. Tius. 1994. Mirabimide E, an Unusual N-Acylpyrrolinone from the Blue-Green Alga Scytonema mirabile: Structure Determination and Synthesis. Journal of the American Chemical Society 116: 8116-8125.
142. Painuly, P., R. Perez, T. Fukai and Y. Shimizu. 1988. The Structure of a Cyclic Peptide Toxin, Cyanoginosin-RR from Microcystis aeruginosa. Tetrahedron Letters 29: 11-14.
143. Panda, D., R. H. Himes, R. E. Moore, L. Wilson and M. A. Jordan. 1997. Mechanism of Action of the Unusually Potent Microtubule Inhibitor Cryptophycin 1. Cancer 36: 12948-12953.
144. Patel, S., M. L. Keohan, M. W. Saif, D. Rushing, L. Baez, K. Feit, R. DeJager and S. Anderson. 2006. Phase II Study of Intravenous TZT-1027 in Patients With Advanced or Metastatic Soft-Tissue Sarcomas With Prior Exposure to Anthracycline-Based Chemotherapy. Cancer 107:2881-2887.
145. Pearson, L., T. Mihali, M. Moffitt, R. Kellmann and B. Neilan. 2010. On the chemistry, toxicology and genetics of the cyanobacterial toxins, microcystin, nodularin, saxitoxin and cylindrospermopsin. Marine Drugs 8: 1650-80.
146. Pegram, R. A., A. R. Humpage, B. A. Neilan, M. T. Runnegar, T. Nichols, R. W. Thacker, S. Pflugmacher, S. M. Etheridge and A. H. Love. 2008. Cyanotoxins Workgroup Report. Advances in Experimental Medicine and Biology 619: 317-381.
147. Pergament, I. and S. Carmeli. 1994. Schizotrin A; a novel antimicrobial cyclic peptide from a cyanobacterium. Tetrahedron Letters 35: 8473-8476.
148. Pettit, G. R., Y. Kamano, C. L. Herald, A. A. Tuinman, F. E. Boettner, H. Kizu, J. M. Schmidt, L. Baczynskyj, K. B. Tomer and R. J. Bontems. 1987. The Isolation and Structure of a Remarkable Marine Animal Antineoplastic Constituent: Dolastatin 10. Journal of the American Chemical Society 109: 6883-6885.
149. Pettit, G. R., S. B. Singh, F. Hogan, P. Lloyd-Williams, D. L. Herald, D. D. Burkett and P. J. Clewlow. 1989. The Absolute Configuration and Synthesis of Natural (-)-Dolastatin 10. Journal of the American Chemical Society 111: 5463-5465.
150. Pettit, G. R., J. K. Srirangam, J. Barkoczy, M. D. Williams, M. R. Boyd, E. Hamel, R. K. Pettit, F. Hogan, R. Bai, J.-C. Chapuis, S. C. McAllister and J. M. Schmidt. 1998. Antineoplastic agents 365. Dolastatin 10 SAR probes. Anti-Cancer Drug Design 13: 243-277.
151. Portmann, C., J. F. Blom, M. Kaiser, R. Brun, F. Jüttner and K. Gademann. 2008. Isolation of Aerucyclamides C and D and Structure Revision of Microcyclamide 7806A: Heterocyclic Ribosomal Peptides from Microcystis aeruginosa PCC 7806 and Their Antiparasite Evaluation. Journal of Natural Products 71: 1891-1896.
152. Prinsep, M. R., R. A. Thomson, M. L. West and B. L. Wylie. 1996. Tolypodiol, an Antiinflammatory Diterpenoid from the Cyanobacterium Tolypothrix nodosa. Journal of Natural Products 59: 786-788.
153. Rastogi, R. P. and R. P. Sinha. 2009. Biotechnological and industrial significance of cyanobacterial secondary metabolites. Biotechnology Advances 27: 521-539.
154. Rath, C. M., J. B. Scaglione, J. D. Kittendorf and D. H. Sherman. 2010. NRPS/PKS Hybrid Enzymes and Their Natural Products. In: Comprehensive Natural Products II: Chemistry and Biology, ed. Lewis Mander and Hung-Wen Liu, 453-492. Elsevier.
155. Raveh, A. and S. Carmeli. 2007. Antimicrobial Ambiguines from the Cyanobacterium Fischerella sp. Collected in Israel. Journal of Natural Products 70: 196-201.
156. Reshef, V., E. Mizrachi, T. Maretzki, C. Silberstein, S. Loya, A. Hizi and S. Carmeli. 1997. New Acylated Sulfoglycolipids and Digalactolipids and Related Known Glycolipids from Cyanobacteria with a Potential To Inhibit the Reverse Transcriptase of HIV-1. Journal of Natural Products 60: 1251-1260.
157. Rezanka, T. and V. M. Dembitsky. 2006. Metabolites Produced by Cyanobacteria Belonging to Several Species of the Family Nostocaceae. Folia Microbiologica 51: 159-182.
158. Riely, G. J., S. Gadgeel, I. Rothman, B. Saidman, K. Sabbath, K. Feit, M. G. Kris and N. A. Rizvi. 2007. A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy. Lung Cancer 55: 181-185.
159. Rinehart, K. L., M. Namikoshi and B. W. Choi. 1994. Structure and biosynthesis of toxins from blue-green algae (cyanobacteria). Journal of Applied Phycology 6: 159-176.
160. Rohr, J. 2006. Cryptophycin Anticancer Drugs Revisited. ACS Chemical Biology 1: 747-750.
161. Rosa, L. A. de la, E. Alvarez-Parrilla and A. Martínez-Martínez. 2007. Biochemistry of Maitotoxin. In: Phycotoxins: Chemistry and Biochemistry, ed. Luis M Botana. Blackwell Publishing. pp. 55-73.
162. Sainis, I., D. Fokas, K. Vareli, A. G. Tzakos, V. Kounnis and E. Briasoulis. 2010. Cyanobacterial cyclopeptides as lead compounds to novel targeted cancer drugs. Marine drugs 8: 629-57.
163. Sanchez, L. M., D. Lopez, B. A. Vesely, G. D. Togna, W. H. Gerwick, D. E. Kyle and R. G. Linington. 2010. Almiramides A-C: Discovery and Development of a New Class of Leishmaniasis Lead Compounds. Journal of Medicinal Chemistry 53: 4187-97.
164. Satake, M. 2007. Chemistry of Maitotoxin. In: Phycotoxins: Chemistry and Biochemistry, ed. Luis M. Botana, 47-53. Blackwell Publishing.
165. Satake, M., M. Murata, T. Yasumoto, T. Fujita and H. Naoki. 1991. Amphidinol, a polyhydroxy-polyene antifungal agent with an unprecedented structure, from a marine dinoflagellate, Amphidinium klebsii. Journal of the American Chemical Society 113: 9859-9861.
166. Schantz, E. J., J. M. Lynch, G. Vayvada, K. Matsumoto and H. Rapoport. 1966. The Purification and Characterization of the Poison Produced by Gonyaulax catenella in Axenic Culture. Biochemistry 5: 1191-1195.
167. Schmidt, E. W., J. T. Nelson, D. A. Rasko, S. Sudek, J. A. Eisen, M. G. Haygood and J. Ravel. 2005. Patellamide A and C biosynthesis by a microcin-like pathway in Prochloron didemni, the cyanobacterial symbiont of Lissoclinum patella. Proceedings of the National Academy of Sciences of the United States of America 102: 7315-7320.
168. Schopf, J. W. and B. M. Packer. 1987. Early Archean (3.3-Billion to 3.5-Billion-Year-Old) Microfossils from Warrawoona Group, Australia. Science 237: 70-73.
169. Schwartz, E., C. F. Hirsch, D. F. Sesin, J. E. Flor, M. Chartrain, E. Fromtling, G. H. Harris, M. J. Salvatore, J. M. Liesch and K. Yudin. 1990. Pharmaceuticals from cultured algae. Journal of Industrial Microbiology 5: 113-124.
170. Schwarzer, D., R. Finking and M. A. Marahiel. 2003. Nonribosomal peptides: from genes to products. Natural Product Reports 20: 275-87.
171. Seattle Genetics, Website on ADC, http://www.seagen.com/technology_adc_tech.shtml, accessed on 25.03.2012.
172. Seiser, T., F. Kamena and N. Cramer. 2008. Synthesis and Biological Activity of Largazole and Derivatives. Angewandte Chemie International Edition 47: 6483-6485.
173. Shimizu, Y. 1993. Microalgal Metabolites. Chemical Reviews 93: 1685-1698.
174. Shimizu, Y. 1996. Microalgal Metabolites: A New Perspective. Annual Reviews in Microbiology 50: 431-465.
175. Shimizu, Y. 2000. Microalgae as a Drug Source. In: Drugs from the Sea, ed. N Fusetani. S. Karger AG. pp. 30-45.
176. Shimizu, Y. 2003. Microalgal metabolites. Current Opinion in Microbiology 6: 236-243.
177. Shin, H. J., H. Matsuda, M. Murakami and K. Yamaguchi. 1997. Circinamide, a Novel Papain Inhibitor from the Cyanobacterium Anabaena circinalis (NIES-41). Tetrahedron 53: 5747-5754.
178. Sielaff, H., G. Christiansen and T. Schwecke. 2006. Natural products from cyanobacteria: Exploiting a new source for drug discovery. IDrugs 9: 119-127.
179. Simmons, T. L., N. Engene, L. D. Ureña, L. I. Romero, E. Ortega-Barría, L. Gerwick and W. H. Gerwick. 2008. Viridamides A and B, Lipodepsipeptides with Antiprotozoal Activity from the Marine Cyanobacterium Oscillatoria nigro-viridis. Journal of Natural Products 71: 1544-50.
180. Simmons, T. L., K. L. McPhail, E. Ortega-Barría, S. L. Mooberry and W. H. Gerwick. 2006. Belamide A, a new antimitotic tetrapeptide from a Panamanian marine cyanobacterium. Tetrahedron Letters 47: 3387-3390.
181. Singh, R. K., S. P. Tiwari, A. K. Rai and T. M. Mohapatra. 2011. Cyanobacteria: an emerging source for drug discovery. The Journal of Antibiotics 64: 401-412.
182. Sivonen, K., N. Leikoski, D. P. Fewer and J. Jokela. 2010. Cyanobactins - ribosomal cyclic peptides produced by cyanobacteria. Applied Microbiology and Biotechnology 86: 1213-1225.
183. Sivonen, K. and G. Jones. 1999. Cyanobacterial Toxins. In: Toxic Cyanobacteria in Water: A guide to their public health consequences, monitoring and management, ed. Ingrid Chorus and Jamie Bartram. WHO.
184. Skulberg, O. M. 2000. Microalgae as a source of bioactive molecules - experience from cyanophyte research. Journal of Applied Phycology 12: 341-348.
185. Smith, C. D., X. Zhang, S. L. Mooberry, G. M. L. Patterson and R. E. Moore. 1994. Cryptophycin: A New Antimicrotubule Agent Active against Drug-resistant Cells. Cancer Research 54: 3779-3784.
186. Stratmann, K., D. L. Burgoyne, R. E. Moore, G. M. L. Patterson and C. D. Smith. 1994. Hapalosin, a Cyanobacterial Cyclic Depsipeptide with Multidrug-Resistance Reversing Activity. Journal of Organic Chemistry 59: 7219-7226.
187. Strieker, M., A. Tanović and M. A. Marahiel. 2010. Nonribosomal peptide synthetases: structures and dynamics. Current Opinion in Structural Biology 20: 234-40.
188. Sturdy, M., A. Krunic, S. Cho, S. Franzblau and J. Orjala. 2010. Eucapsitrione, an Anti-Mycobacterium tuberculosis Anthraquinone Derivative from the Cultured freshwater Cyanobacterium Eucapsis sp. Journal of natural products 73: 1441-1443.
189. Suenaga, K., T. Mutou, T. Shibata, T. Itoh, H. Kigoshi and K. Yamada. 1996. Isolation and Stereostructure of Aurilide, a Novel Cyclodepsipeptide from the Japanese Sea Hare Dolabella auricularia. Tetrahedron Letters 37: 6771-6774.
190. Tan, L. T. 2007. Bioactive natural products from marine cyanobacteria for drug discovery. Phytochemistry 68: 954-979.
191. Tan, L. T. 2010. Filamentous tropical marine cyanobacteria: a rich source of natural products for anticancer drug discovery. Journal of Applied Phycology 22: 659-676.
192. Taori, K., S. Matthew, J. R. Rocca, V. J. Paul and H. Luesch. 2007. Lyngbyastatins 5-7, Potent Elastase Inhibitors from Floridian Marine Cyanobacteria, Lyngbya spp. Journal of Natural Products 70: 1593-1600.
193. Taori, K., V. J. Paul and H. Luesch. 2008. Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp. Journal of the American Chemical Society 130: 1806-1807.
194. Teruya, T., H. Sasaki, H. Fukazawa and K. Suenaga. 2009. Bisebromoamide, a Potent Cytotoxic Peptide from the Marine Cyanobacterium Lyngbya sp.: Isolation, Stereostructure, and Biological Activity. Organic Letters 11: 5062-5065.
195. Tidgewell, K., B. R. Clark and W. H. Gerwick. 2010. The Natural Products Chemistry of Cyanobacteria. In: Comprehensive Natural Products II: Chemistry and Biology, ed. Lewis Mander and Hung-Wen Liu. Elsevier. pp. 141-188.
196. Trimurtulu, G., I. Ohtani, G. M. L. Patterson, R. E. Moore, T. H. Corbett, Frederick A. Valeriote and Lisa Demchik. 1994. Total Structures of Cryptophycins, Potent Antitumor Depsipeptides from the Blue-Green Alga Nostoc sp. Strain GSV 224. Journal of the American Chemical Society 116: 4729-4737.
197. Tripathi, A., J. Puddick, M. R. Prinsep, P. P. F. Lee and L. T. Tan. 2009. Hantupeptin A, a Cytotoxic Cyclic Depsipeptide from a Singapore Collection of Lyngbya majuscula. Journal of Natural Products 71: 29-32.
198. Tripathi, A., J. Puddick, M. R. Prinsep, M. Rottmann, K. P. Chan, D. Y.-K. Chen and L. T. Tan. 2011. Lagunamide C, a cytotoxic cyclodepsipeptide from the marine cyanobacterium Lyngbya majuscula. Phytochemistry 72: 2369-2375.
199. Vacek, J., J. Hrbáč, J. Kopecký and J. Vostálová. 2011. Cytotoxicity and Pro-Apoptotic Activity of 2,2'-Bis[4,5-bis(4-hydroxybenzyl)-2-(4-hydroxyphenyl)cyclopent-4-en-1,3-dione], a Phenolic Cyclopentenedione Isolated from the Cyanobacterium Strain Nostoc sp. str. Lukešová 27/97. Molecules 16: 4254-4263.
200. Verdier-Pinard, P., J.-Y. Lai, H.-D. Yoo, J. Yu, B. Marquez, D. G. Nagle, M. Nambu, J. D. White, J. R. Falck, W. H. Gerwick, B. W. Day and E. Hamel. 1998. Structure-activity Analysis of the Interaction of Curacin A, the Potent Colchicine Site Antimitotic Agent, with Tubulin and Effects of Analogs on the Growth of MCF-7 Breast Cancer Cells. Molecular Pharmacology 53: 62-76.
201. Wagner, M. M., C. Shih, A. Jordan and D. C. Williams. 1999. In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines. Cell Proliferation 43: 115-125.
202. Watanabe, M. F., K.-i. Harada, W. W. Carmichael and H. Fujiki. 1995. Toxic Microcystis. CRC Press.
203. Welker, M. and H. von Döhren. 2006. Cyanobacterial peptides - Nature's own combinatorial biosynthesis. FEMS microbiology reviews 30: 530-563.
204. Whitton, B. A. and M. Potts, eds. 2000. The Ecology of Cyanobacteria: Their Diversity in Time and Space. Springer.
205. Wiegand, C. and S. Pflugmacher. 2005. Ecotoxicological effects of selected cyanobacterial secondary metabolites a short review. Toxicology and Applied Pharmacology 203: 201-218.
206. Williams, P. G., W. Y. Yoshida, M. K. Quon, R. E. Moore and V. J. Paul. 2003. The Structure of Palau'amide, a Potent Cytotoxin from a Species of the Marine Cyanobacterium Lyngbya. Journal of Natural Products 66: 1545-1549.
207. Wipf, P., J. T. Reeves and B. W. Day. 2004. Chemistry and biology of curacin A. Current Pharmaceutical Design 10: 1417-37.
208. Wipf, P., J. T. Reeves, R. Balachandran and B. W. Day. 2002. Synthesis and Biological Evaluation of Structurally Highly Modified Analogues of the Antimitotic Natural Product Curacin A. Journal of Medicinal Chemistry 45: 1901-1917.
209. Wu, A. M. and P. D. Senter. 2005. Arming antibodies: prospects and challenges for immunoconjugates. Nature Biotechnology 23: 1137-1146.
210. Wu, M., T. Okino, L. M. Nogle, B. L. Marquez, R. T. Williamson, N. Sitachitta, F. W. Berman, T. F. Murray, K. McGough, R. James, K. Colsen, T. Asano, F. Yokokawa, T. Shioiri and W. H. Gerwick. 2000. Structure, Synthesis, and Biological Properties of Kalkitoxin, a Novel Neurotoxin from the Marine Cyanobacterium Lyngbya majuscula. Journal of the American Chemical Society 122: 12041-12042.
211. Xiong, S., J. Fa and K. Kitazato. 2010. The antiviral protein cyanovirin-N: the current state of its production and applications. Applied microbiology and Biotechnology 86: 805-812.
212. Ying, Y., K. Taori, H. Kim, J. Hong and H. Luesch. 2008. Total synthesis and molecular target of largazole, a histone deacetylase inhibitor. Journal of the American Chemical Society 130: 8455-9.
213. Younes, A., U. Yasothan and P. Kirkpatrick. 2012. Brentuximab vedotin. Nature Reviews Drug Discovery 11: 19-20.
214. Zainuddin, E. N., R. Jansen, M. Nimtz, V. Wray, M. Preisitsch, M. Lalk and S. Mundt. 2009. Lyngbyazothrins A-D, Antimicrobial Cyclic Undecapeptides from the Cultured Cyanobacterium Lyngbya sp. Journal of Natural Products 72: 1373-8.
215. Zhang, W. and Y. Tang. 2008. Combinatorial Biosynthesis of Natural Products. Journal of Medicinal Chemistry 51: 2629-2633.
216. Ziemert, N., K. Ishida, A. Liaimer, C. Hertweck and E. Dittmann. 2008. Ribosomal Synthesis of Tricyclic Depsipeptides in Bloom-Forming Cyanobacteria. Angewandte Chemie International Edition 47: 7756-7759.
217. Ziemert, N., K. Ishida, A. Weiz, C. Hertweck and E. Dittmann. 2010. Exploiting the Natural Diversity of Microviridin Gene Clusters for Discovery of Novel Tricyclic Depsipeptides. Applied and Environmental Microbiology 76: 3568-3574.
218. Zurawell, R. W., H. Chen, J. M. Burke and E. E. Prepas. 2005. Hepatotoxic cyanobacteria: a review of the biological importance of microcystins in freshwater environments. Journal of Toxicology and Environmental Health. Part B 8: 1-37.